Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.004
Sell
RSI(14)
29.040
Sell
STOCH(KDJ)(9,3,3)
68.783
Buy
ATR(14)
0.114
Low Volatility
CCI(14)
48.760
Neutral
Williams %R
77.404
Sell
TRIX(12,20)
-4.449
Sell
StochRSI(14)
85.031
Overbought
Search
Soligenix Inc
SNGXAdd to Watchlist
0.360USD
-0.046-11.31%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
6.02MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Soligenix Inc
Currency: USD Updated: 2026-05-14Key Insights
Soligenix Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 132 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Soligenix Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Soligenix Inc Highlights
StrengthsRisks
Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is -0.30, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 528.92K shares, decreasing 67.34% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.41.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
6.000
Target Price
+1553.80%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-14The current financial score of Soligenix Inc is 6.59, ranking 225 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.84
Operational Efficiency
2.69
Growth Potential
6.36
Shareholder Returns
7.03
Soligenix Inc's Company Valuation
Currency: USD Updated: 2026-05-14The current valuation score of Soligenix Inc is 8.27, ranking 53 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.30, which is -51.93% below the recent high of -0.14 and -583.18% above the recent low of -2.05.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 132/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-14The current earnings forecast score of Soligenix Inc is 8.00, ranking 159 out of 382 in the Biotechnology & Medical Research industry. The average price target is 17.50, with a high of 25.00 and a low of 10.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
6.000
Target Price
+1553.80%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Soligenix Inc
SNGX
1
CRISPR Therapeutics AG
CRSP
29
Beigene Ltd
ONC
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-14The current price momentum score of Soligenix Inc is 6.28, ranking 275 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.13 and the support level at -0.02, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
0.344
Buy
MA10
0.331
Buy
MA20
0.650
Sell
MA50
0.970
Sell
MA100
1.117
Sell
MA200
1.584
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-14The current institutional shareholding score of Soligenix Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 5.13%, representing a quarter-over-quarter decrease of 64.45%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-14The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Soligenix Inc is 2.27, ranking 231 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.32. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.34
VaR
+9.73%
240-Day Maximum Drawdown
+94.35%
240-Day Volatility
+181.20%
Return
Best Daily Return
60 days
+17.15%
120 days
+17.15%
5 years
+1180.81%
Worst Daily Return
60 days
-70.25%
120 days
-70.25%
5 years
-91.09%
Sharpe Ratio
60 days
-1.29
120 days
-1.01
5 years
+0.36
Risk Assessment
Maximum Drawdown
240 days
+94.35%
3 years
+98.21%
5 years
+99.90%
Return-to-Drawdown Ratio
240 days
-0.86
3 years
-0.33
5 years
-0.20
Skewness
240 days
+5.35
3 years
+12.12
5 years
+29.54
Volatility
Realised Volatility
240 days
+181.20%
5 years
+163.37%
Standardised True Range
240 days
+48.92%
5 years
+1366.38%
Downside Risk-Adjusted Return
120 days
-82.30%
240 days
-82.30%
Maximum Daily Upside Volatility
60 days
+135.84%
Maximum Daily Downside Volatility
60 days
+158.28%
Liquidity
Average Turnover Rate
60 days
+21.40%
120 days
+14.97%
5 years
--
Turnover Deviation
20 days
-39.34%
60 days
-73.69%
120 days
-81.59%
Peer Comparison
Biotechnology & Medical Research
Soligenix Inc
SNGX
6.26 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
